USFDAAug 12, 2026, 08:16 AM
Autonomix Medical Completes GLP Pre-Clinical Study for FDA Submission
AI Summary
Autonomix Medical, Inc. announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study. This study evaluated the safety, functionality, and performance of the Autonomix platform across multiple anatomical targets in porcine models, with final histology and laboratory analyses supporting positive outcomes. The data generated from this study is a significant regulatory milestone and is expected to support the Company's upcoming submissions to the U.S. Food and Drug Administration (FDA) for its precision nerve-targeted treatments.
Key Highlights
- Successfully completed Good Laboratory Practice (GLP) pre-clinical study.
- Study evaluated safety, functionality, and performance of the Autonomix platform.
- Conducted in accordance with FDA Good Laboratory Practice standards in porcine models.
- Final histopathology and laboratory analyses supported positive safety and performance outcomes.
- Data generated from the study is expected to support Autonomix's FDA submissions.
- Represents a critical step in the Company's regulatory and clinical development strategy.
Price Impact
More from AMIX